Compare TMUS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMUS | MRK |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.7B | 268.7B |
| IPO Year | N/A | N/A |
| Metric | TMUS | MRK |
|---|---|---|
| Price | $186.05 | $108.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $260.94 | $114.86 |
| AVG Volume (30 Days) | 4.9M | ★ 11.4M |
| Earning Date | 02-11-2026 | 02-03-2026 |
| Dividend Yield | 2.20% | ★ 3.11% |
| EPS Growth | 18.54 | ★ 58.08 |
| EPS | ★ 10.38 | 7.56 |
| Revenue | ★ $85,847,000,000.00 | $64,235,000,000.00 |
| Revenue This Year | $10.51 | $1.97 |
| Revenue Next Year | $7.35 | $4.71 |
| P/E Ratio | $17.86 | ★ $14.45 |
| Revenue Growth | ★ 7.30 | 1.68 |
| 52 Week Low | $181.36 | $73.31 |
| 52 Week High | $276.49 | $112.90 |
| Indicator | TMUS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 54.86 |
| Support Level | $181.36 | $106.93 |
| Resistance Level | $192.69 | $111.97 |
| Average True Range (ATR) | 4.21 | 2.76 |
| MACD | -0.95 | -0.45 |
| Stochastic Oscillator | 21.09 | 33.80 |
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the US. T-Mobile now serves 85 million postpaid and 26 million prepaid phone customers, equal to around 30% of the US retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves 7 million residential and business customers with its wireless network. It also serves nearly 1 million fiber broadband customers through joint ventures with fiber network owners. T-Mobile owns a stake in these firms, which provide wholesale access to their networks. In addition, T-Mobile provides wholesale services to wireless resellers.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).